



## Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

November 9, 2022

BOSTON, Mass.--(BUSINESS WIRE)--Nov. 9, 2022--

[Astria Therapeutics, Inc.](#) (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the upcoming Jefferies London Healthcare Conference on Wednesday, November 16th at 7:25am GMT.

A webcast of the presentation can be accessed at the following link: <https://www.wsj.com/webcast/jeff255/atxs/1877472>. An archived replay of the presentation will be available in the investors section of [www.astriatx.com](http://www.astriatx.com) for 30 days following the event.

### **About Astria Therapeutics:**

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Learn more about our company on our website, [www.astriatx.com](http://www.astriatx.com), or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20221109005180/en/>

### **Investor relations:**

Andrea Matthews

[investors@astriatx.com](mailto:investors@astriatx.com)

### **Media:**

Elizabeth Higgins

[media@astriatx.com](mailto:media@astriatx.com)

Source: Astria Therapeutics, Inc.